Ferenc E Mózes, Jenny A Lee, Yasaman Vali, Emmanuel A Selvaraj, Arjun N A Jayaswal, Jérôme Boursier, Victor de Lédinghen, Monica Lupșor-Platon, Yusuf Yilmaz, Wah-Kheong Chan, Sanjiv Mahadeva, Thomas Karlas, Johannes Wiegand, Shalimar, Emmanouil Tsochatzis, Antonio Liguori, Vincent Wai-Sun Wong, Dae Ho Lee, Adriaan G Holleboom, Anne-Marieke van Dijk, Anne Linde Mak, Hannes Hagström, Camilla Akbari, Masashi Hirooka, Dong Hyeon Lee, Won Kim, Takeshi Okanoue, Toshihide Shima, Atsushi Nakajima, Masato Yoneda, Paul J Thuluvath, Feng Li, Annalisa Berzigotti, Yuly P Mendoza, Mazen Noureddin, Emily Truong, Céline Fournier-Poizat, Andreas Geier, Theresa Tuthill, Carla Yunis, Quentin M Anstee, Stephen A Harrison, Patrick M Bossuyt, Michael Pavlides
BACKGROUND & AIMS: There is a need to reduce the screen failure rate (SFR) in metabolic dysfunction-associated steatohepatitis (MASH) clinical trials (MASH+F2-3; MASH+F4) and identify people with high-risk MASH (MASH+F2-4) in clinical practice. We aimed to evaluate non-invasive tests (NITs) screening approaches for these target conditions. METHODS: This was an individual participant data meta-analysis for the performance of NITs against liver biopsy for MASH+F2-4, MASH+F2-3 and MASH+F4...
April 4, 2024: Liver International: Official Journal of the International Association for the Study of the Liver